Imipenem/cilastatin/relebactam (Recarbrio®). HTA ID: 20040

Assessment Status Rapid Review Complete
HTA ID 20040
Drug Imipenem/cilastatin/relebactam
Brand Recarbrio®
Indication For the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.
Assessment Process
Rapid review commissioned 31/08/2020
Rapid review completed 21/10/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imipenem/cilastatin/relebactam compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.